The insulin-like growth factor-1 (IGF-1) signaling axis is important for cell growth, differentiation and survival and increased serum IGF is a risk factor for prostate and other cancers. To study IGF-1 action on the prostate, we created transgenic (PB-Des) mice that specifically express human IGF-1 des in prostate epithelial cells. This encodes a mature isoform of IGF-1 with decreased affinity for IGF binding proteins (IGFBP) due to a 3-amino acid deletion in the N terminus. Expression of IGF-1 des was sufficient to cause hyperplastic lesions in all mice, however the welldifferentiated lesions did not progress to adenocarcinoma within a year. Remarkably, crossing the PB-Des mice to an established model of prostate cancer delayed progression of organ-confined tumors and emergence of metastatic lesions in young mice. While dissemination of metastatic lesions was widespread in old bigenic mice we did not detect IGF-1 des in poorly differentiated primary tumors or metastatic lesions. Expression of endogenous IGF-1 and levels of P-Akt and P-Erk were reduced independent of age. These data suggest that increased physiologic levels of IGF-1 facilitate the emergence of hyperplastic lesions while imposing a strong IGF-1-dependent differentiation block. Selection against IGF-1 action appears requisite for progression of localized disease and metastogenesis.
Introduction
The insulin-like growth factor (IGF) signaling axis includes two IGF ligands (IGF-1 and IGF-2), two receptors (IGF1R and IGF2R) and at least six binding proteins (IGFBP 1-6) (Le Le Roith and Roberts, 2003; Yakar et al., 2005) . Deregulated IGF-1 signaling has been associated with the risk of breast, colon, lung, prostate and other cancers (Pollak et al., 2004; Foulstone et al., 2005) . Epidemiologic and molecular analyses have shown elevated serum IGF-1 associated with prostate cancer risk in prospective and case-control studies (Chan et al., 1998 (Chan et al., , 2002 Shaneyfelt et al., 2000; Platz et al., 2005) . Elevated levels of IGFBP-2 and reduced levels of IGFBP-3 in patients have also been observed (Pollak et al., 2004) . Paradoxically, decreased levels of IGF-1R have been reported in metastatic lesions of prostate (Chott et al., 1999; Forbes et al., 2004) , breast (Schnarr et al., 2000) and liver (Nakamura et al., 2004) cancers, suggesting that both activation and suppression of the IGF-1 signaling network can contribute to the progression of clinical disease.
Associations between IGF-1 and prostate disease appear conserved through evolution as prostatic IGF-1 mRNA levels increase with early cancer progression in the genetically engineered mouse (GEM) transgenic adenocarcinoma of the mouse prostate (TRAMP) model of prostate cancer and serum IGFBP-2 is significantly elevated in late stage disease (Kaplan et al., 1999) . This is of particular interest since haploinsufficiency of PTEN also promotes progression of prostate cancer in this model (Kwabi-Addo et al., 2001 ) and serum IGFBP-2 levels may portend PTEN status and PI3K Akt pathway activation in cancer patients (Mehrian-Shai et al., 2007) . TRAMP mice carrying the lit germ-line mutation that inactivates the GHRH receptor (GHRH-R) also showed delayed prostate cancer progression and prolonged survival owing to reduced circulating levels of both GH and IGF-1 (Majeed et al., 2005) .
Growth, development and differentiation of the prostate are strongly influenced by stromal-epithelial interactions mediated by polypeptide growth factors (Cunha and Donjacour, 1989; Byrne et al., 1996; Wu et al., 2003; Evangelou et al., 2004) . To address the consequence of deregulated IGF signaling at the level of prostate epithelium and study the role of IGF-1 on epithelial differentiation and prostate cancer progression we generated novel lines of transgenic mice (PB-Des) that express a des(1-3) IGF-1 isoform (IGF-1 des ) that has decreased interaction with IGF binding proteins (IGFBP) by virtue of the 3-amino acid deletion in the N terminus of the mature protein. To examine the longterm consequence of deregulated IGF-1 signaling in the context of abrogated p53 and Rb-family functions commonly associated with clinical prostate cancer (MacGrogan and Bookstein, 1997) we also crossed the PB-Des mice to TRAMP mice that express the SV40 early genes (T and t antigens) under PB control (Greenberg et al., 1995; Kaplan-Lefko et al., 2003) .
Consistent with clinical data, IGF-1 des expression appeared sufficient to cause spontaneous atypical prostate hyperplasia. However the lesions did not progress to overt neoplasia within 1 year. In [TRAMP Â PB-Des]F1 mice the temporal progression of pathology was actually slowed. Paradoxically older [TRAMP Â PB-Des]F1 mice eventually developed more advanced adenocarcinomas and more widespread metastatic deposits than controls. Molecular analysis of primary and metastatic tissues from older mice showed loss of IGF-1 des expression providing evidence to support dual roles for IGF-1 action in progression of prostate confined and metastatic disease states.
Results

PB-Des transgenic mice
We generated three independent lines of PB-Des transgenic mice ([5299] , [5305] and [6206] , Figure 1 ). Human IGF-1 des was chosen because of a reduced affinity for IGFBPs but normal affinity for the cognate (IGF-1R) receptor (Oh et al., 1993) . As shown in Figure 1 , the IGF-1 des transgene was expressed in the dorsolateral (DLP) and ventral (VP) prostate lobes in [5299] and [5305] . Expression in [6206] was restricted to the VP. Since IGF-1 des expression in the anterior prostate (AP) was consistently low (Figure 1 ), further characterization of AP was not performed. Hereafter we focus on [5305] as these mice reproducibly exhibited the highest level of IGF-1 des expression in DLP and VP (Figure 1b) . Line [5305] showed the highest levels of PB driven expression in the DLP and VP ( Figure 1c ) consistent with previous reports (Greenberg et al., 1994) . The doublet observed with the PB þ 1/ þ 28 and SV40BII primer set was due to alternative splice acceptors in the cleavage and polyadenylation sequence. PCR analysis verified that the IGF-1 des transcript was appropriately transcribed and spliced (data not shown).
A human-specific IGF-1 immunoradiometric assay (IRMA) detected sub-physiologic levels of IGF-1 des in Figure 1 The PB-Des mice. (a) The PB-Des transgene consists of the minimal rat probasin (PB) regulatory elements (À426 to þ 28) placed upstream of an IGF-1mini-gene that was initially described (Hadsell et al., 1996) . The location and orientation of the primers used for PCR are denoted PB þ 1/ þ 28, DES7, DES8, DES11, DES12, DES16, BII (see Table 1 (Hadsell et al., 1996) were used as positive controls.
We were unable to detect significant differences in the genitourinary (GU) tract weight (normalized to body weight) between PB-Des mice and nontransgenic littermates at any age (25-66 weeks old) in line 5305 (PB-Des, 0.019 ± 0.001 g, n ¼ 65; nontransgenic, 0.018 ± 0.001 g, n ¼ 43) or line 6206 (PB-Des, 0.015 ± 0.002 g, n ¼ 4; nontransgenic, 0.014±0.0005 g, n ¼ 5). However, H&E-stained prostate sections routinely demonstrated disorganized epithelial cells, epithelial stratification, areas of epithelial tufting with teardrop shaped cells with elongated nuclei, nuclear atypia and hyperchromatic nuclei (Figures 2b-f) consistent with mouse PIN (mPIN) without demonstrated invasion or metastases (Shappell et al., 2004) . As shown in Figure 3a , the number of abnormal acini in PB-Des mice (49.3 ± 2.4%) was significantly increased compared to age-matched nontransgenic littermates (35.2±2.6%; P ¼ 0.004 by Bonferroni/Dunn). All PB-Des mice exhibited increased numbers of abnormal acini, specifically in the LP (55.8±4.2%) compared to controls (36.1±4.6%, P ¼ 0.0061 by Bonferroni/Dunn; Figure 3b ). Trichrome staining revealed intact basement membranes within all areas (data not shown).
We analysed expression of IGF1R and downstream mediators IRS-1, IRS-2, Akt and MAPK (p44/42) in samples procured from the DLP and VP of PB-Des and nontransgenic mice at 20-30 weeks of age. As shown in Figure 4 , we were unable to detect significant differences in IGF1R or IRS-1 expression between PB-Des and controls. Interestingly, expression of IRS-2 was significantly lower (Po0.01 by Bonferroni/Dunn) in the DLP of PB-Des mice compared to controls and levels of IGF1R, IRS-1 and IRS-2 were lower in DLP than VP (Figures 4a-c) . Consistent with increased IGF-1/IGF-1R activity, the P-Akt (Ser 473) levels were significantly (Po0.05 by Bonferroni/Dunn) higher in VP of PB-Des mice compared to the level in VP in controls ( Figure 5 ).
Prostate cancer progression and metastases
The prostate glands of PB-Des mice remained tumor free for 1 year, so we crossed these mice to the TRAMP model to see if IGF-1 des could accelerate prostate tumor progression. As shown in Figure 6 and Tables 2 and 3 , we were unable to detect any significant difference in overall cancer incidence, relative GU weight or in the To quantitate the phenotype, the number of abnormal acini was counted at Â 400 magnification in H&E-stained sections from the dorsal (DP), lateral (LP) and ventral (VP) prostates of 1-year old PB-Des mice (n ¼ 16) and age-matched nontransgenic littermates (n ¼ 9). Acini were considered abnormal if they contained nuclear atypia, hyperplasia or epithelial stratification. The number of abnormal acini was normalized to the total number of acini counted. The percent abnormal acini represent an average of acini counted by two independent blinded observers. The percent abnormal acini were examined for the total prostate (a) or by individual lobe (b). *, significantly different (Pp0.006) from control DLP (Bonferroni/Dunn analysis of variance). (Table 3) indicating that IGF-1 des expression was delaying tumor progression. This property apparently was restricted to the younger mice as the incidence of poorly differentiated prostate cancer in [TRAMP Â PBDes]F1 mice by 24 weeks of age (6/7; 86%) approached that of TRAMP controls although TRAMP tumors were still of higher grade (Figure 6 ). By 24 weeks of age [TRAMP Â PB-Des]F1 mice had metastatic deposits in the pelvic lymph nodes, renal lymph nodes, lungs, salivary glands and liver (Table 3) while TRAMP littermates had metastatic deposits primarily in their pelvic lymph nodes (5/7; 72%).
To explain the apparent paradox we determined the status of transgene (IGF-1 des ) and endogenous (mIGF-1) RNA expression in a subset of the primary and metastatic prostate cancers. As shown in Figure 7 , we found robust IGF-1 des expression in mPIN and welldefined (WD) tumors from 15 to 24 weeks old [TRAMP Â PB-Des]F1 mice but did not detect expression of IGF-1 des in any pregnancy-dependent (PD) tumor or metastatic lesions at any age. The advanced PD tumors and metastatic lesions in [TRAMP Â PBDes]F1 mice also expressed reduced levels of endogenous mIGF-1 but maintained significant levels of SV40 Tantigen expression. Protein levels were normalized to b-actin levels. Mean ( ± s.e.m.) levels were expressed relative to the DLP from nontransgenic mice that was assigned a value of 1. IGF1R and IRS-1: PB-Des, n ¼ 7 with two mice analysed in duplicate; Control, n ¼ 5. IRS-2: PB-Des, n ¼ 11 with three mice analysed in duplicate and one mouse analysed in triplicate; Control, n ¼ 9 with four mice analysed in duplicate. *, significantly different (Po0.0001) from control DLP (Bonferroni/Dunn analysis of variance). Akt protein levels were normalized to b-actin levels, and Phospho-Akt protein levels were normalized to Akt levels. Mean ( ± s.e.m.) levels were expressed relative to the DLP from nontransgenic mice, which was assigned a value of 1. PB-Des, n ¼ 7 with 2 mice analysed in duplicate; Control, n ¼ 5. 
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Discussion
Epidemiologic studies have demonstrated that the risk of developing prostate cancer is associated with elevated serum IGF-1 (Chan et al., 1998; Pollak et al., 2004) . While also linked to lung, premenopausal breast and colorectal cancers, such associations are modest, vary between cancer sites (Pollak et al., 2004; Renehan et al., 2004 ) and a causative relationship has not yet been conclusively demonstrated. However, a recent report has shown that a lit germ-line mutation inhibits progression of spontaneous prostate cancer in an autochthonous system, suggesting that reduced GH levels and/or one or more of its downstream targets (including IGF-1), appear to be very important in controlling prostate cancer progression.
A direct role of organ restricted IGF signaling has been investigated in prostate and other cancers. Enforced expression of full length human IGF-1 under control of the bovine K5 promoter (BK5.IGF1) in mouse basal epithelial cells caused prostate cancer in a majority of mice over 6 months of age (DiGiovanni et al., 2000b) as well as squamous papillomas (DiGiovanni et al., 2000a) . However, the prostate tumors often developed focally and some early lesions expressed a small cell phenotype consistent with tumors of neuroendocrine origin. The adenocarcinomas maintained well-differentiated appearance up to 14 months of age and metastases or androgen withdrawal resistant tumors were not reported. Enforced expression of IGF-1 des in the mammary epithelium under control of the rat whey acidic protein (rWAP) promoter caused incomplete mammary involution, ductile hypertrophy and loss of secretory lobules associated with increased deposition of collagen in young mice while older mice developed adenocarcinomas by 23 months of age after multiple lactations (Hadsell et al., 2000) . Recently, mice that express a constitutively active CD8-IGF-1R fusion transgene under mouse mammary tumor virus long terminal repeat (MMTV-LTR) control Body weights and GU weights were recorded at sacrifice. Relative GU weights (GU weight normalized to body weight) are shown for nontransgenic (NT), PB-Des, TRAMP and TRAMP Â PB-Des bigenic mice at 6, 12, 18 and 24 weeks of age. The mean ( ± s.e.m.) relative GU weight was expressed relative to the 6-week nontransgenic cohort, which was assigned a value of 1. NT: 6 weeks, n ¼ 7; 12 weeks, n ¼ 21; 18 weeks, n ¼ 11; 24 weeks, n ¼ 17; PB-Des: 6 weeks, n ¼ 6; 12 weeks, n ¼ 9; 18 weeks, n ¼ 15; 24 weeks, n ¼ 7; TRAMP: 6 weeks, n ¼ 7; 12 weeks, n ¼ 9; 18 weeks, n ¼ 11; 24 weeks, n ¼ 7; TRAMP Â PB-Des: 6 weeks, n ¼ 8; 12 weeks, n ¼ 19; 18 weeks, n ¼ 14; 24 weeks, n ¼ 7. 
IGF-1 and Prostate Cancer
PJ Kaplan-Lefko et al des -specific product of 347 bp. (b) Expression of endogenous mIGF-1 and SV40 T-antigen transgene expression were determined by RT-PCR from tissues as in (a) where enough material was remaining. Primers mIGF-1F and mIGF-1R were used to amplify an endogenous mIGF-1specific PCR product of 318 bp in size, while PB þ 1/ þ 28 and SV40B11 were used to amplify a 400 bp fragment from SV40 large-T (T) antigen. All PCR products were fractionated on agarose gels and visualized using Ethidium Bromide. Equal input was verified by internal control RT-PCR expression of the mouse L19 gene.
IGF-1 and Prostate Cancer PJ Kaplan-Lefko et al showed aberrant mammary gland development with salivary and mammary adenocarcinomas as early as 8 weeks of age (Carboni et al., 2005) . Although the MMTV-LTR will express at a very early age, the data show how the temporal, spatial and level of IGF-1 and IGF1R expression can produce a range of phenotypes.
There is cause to discern between systemic and localized IGF-1 action. For example, in the BK5.IGF-1 mice IGF-1 is expressed in almost all basal epithelial cells and coordinately elevated serum levels of IGF-1 and IGFBP3 are observed. This is very similar to the situation in acromegalic patients (Colao et al., 1999) even though they do not appear to be predisposed to develop prostate cancer. Since the BK5-IGF-1 mice develop hyperplasia, PIN lesions and prostatic adenocarcinoma as well as skin cancer and other anomalies raises the possibility that the phenotype could reflect signaling events beyond epithelial autonomous activation of IGF-1R. Moreover, these findings contrast those of the MT-rPRL mice that display elevated levels of serum prolactin, IGF-1 and testosterone because of the metallothionein promoter driving a rat prolactin transgene (Wennbo et al., 1997a, b) . Interestingly, the prostate glands of both MT-rPRL and PB-Des mice were similarly enlarged and hyperplastic, but not transformed and supported a role for IGF-1 in promoting local well-differentiated prostate disease and that elevated albeit still physiological levels of IGF-1 are generally insufficient to cause prostate cancer.
The consequence of deregulated IGF action within the microenvironment of the prostate may lead to a variety of cell-type specific autonomous changes that ultimately contribute to advanced prostate cancer. Presumably some of these changes could occur in the stem-cell niche reported to exist within the prostate gland (Hudson, 2004; Burger et al., 2005; Xin et al., 2005) that may also contribute to the emergence of aggressive poorly differentiated metastatic disease in TRAMP following hormone withdrawal therapy (Gingrich et al., 1996; Huss et al., 2005) . This is also consistent with the reported role for IGF1R in survival and self-renewal of pluripotent stem cells (Bendall et al., 2007) .
That enforced expression of IGF-1 des could slow the progression of autochthonous prostate cancer in model systems is in remarkable agreement with a prospective study demonstrating a strong association between more differentiated lower grade (Gleason Score o7) clinical cancer and elevated serum IGF-1 levels (Chan et al., 2002) . In fact, our observations also agree with established associations between an elevated ratio of IGF-1 to IGFBP3 and the risk of developing extraprostatic and distant metastasis (Chan et al., 2002) . The data from our models also support studies in the LNCaP model that showed reconstitution of IRS-1-increased cell adhesion and decreased motility while restoration of IGF-1R levels caused growth arrest (Reiss et al., 2000) . Thus, IGF signaling axis can differentially influence both tumor differentiation and tumor progression in both mice and clinically derived models. This underscores the need to further elucidate the systemic and tissue specific roles of IGF-1 and cancer. Indeed, a parallel study (Sutherland et al., submitted) using conditional targeting and ablation strategies addresses some of these possibilities. 
PJ Kaplan-Lefko et al The observation that the widely disseminated lesions in aged [TRAMP Â PB-Des]F1 mice exhibit a complete loss of IGF-1 des transgene expression is in general agreement with other reports (Kaplan et al., 1999; Damon et al., 2001; Plymate et al., 2004) and supports the hypothesis that suppressing IGF-1 signals below a 'differentiation' threshold is requisite for well-differentiated cancers to progress to more aggressive states. We suggest the term 'hurdle hypothesis' to describe the phenomenon and propose that the height of the hurdle defines the extent to which a factor contributes to differentiation and determines how aggressive a cancer must become to overcome the barrier and achieve malignancy. While we cannot completely rule out the possibility that PD and metastatic lesions might originate from an as yet undefined cancer stem cell population, recent reports suggest that IGF1R is a marker of less differentiated pluripotent human embryonic stem cells and functionally promotes clonogenic capacity and self-renewal by blocking apoptosis and promoting proliferation (Bendall et al., 2007) . It is also interesting to note that a significant association was recently reported between high IGF-1R expression and favorable outcome in highly malignant soft tissue sarcomas (Ahlen et al., 2005) . Both lines of evidence support our finding that once a cancer has been initiated, the loss of IGF-1 signaling promotes progression. These findings are particularly relevant when viewed in context of recent initiatives to abrogate the IGF-1 axis in prostate and other cancers using small molecule inhibitors and other therapeutic strategies. Clearly, a better understanding of the consequences of IGF-1 action during cancer initiation and progression will be necessary to help guide this important area of translational research.
Experimental procedures
Details describing transgene construction, generation and screening of transgenic mice, analysis of transgene expression, histologic analysis, western blot analysis, generation and analysis of bigenic mice and statistical analysis can be found in Supplementary Data.
